Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[Buddhahead]

Alzheimer’s disease and type 2 diabetes via chronic inflammatory mechanisms, Science Direct, Saudi Journal of Biological Sciences, Gohar Mushtaqa, , , Jalaluddin A. Khana, Taha A. Kumosania, b, Mohammad A. Kamalb, a Department of Biochemistry, Faculty of Science, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia
b King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 80216, Jeddah 21589, Saudi Arabia, Available online 23 May 2014
Excerpt:
"The transcription factor NF?B (nuclear factor kappa-light-chain-enhancer of activated B cells) is another protein complex besides TNF-a that is considered as a primary regulator of inflammatory process. NF?B is found in almost all cell types, including the nervous system. NF?B regulates the expression of many genes which encode proteins that play a decisive role in the process of inflammation. Recent findings have shown the involvement of NF?B in brain processes, especially in neurodegenerative diseases such as AD ( O’Neill and Kaltschmidt, 1997). For instance, Aß peptide found in the plaques of AD patient brain sections has been shown to be a potent activator of NF?B in primary neurons and in neurons in the close proximity of early plaques from AD patients ( Kaltschmidt et al., 1997). The distribution of NF?B was also explored histochemically (using polyclonal antibody against the NF?B p65 subunit) in postmortem brains of AD patients as well as healthy controls. In normal control brains, very weak staining of some neurons was noticed. However, in the AD patients’ brains, strong neuronal staining for NF?B was observed in neurons, neurofibrillary tangles and dystrophic neuritis, particularly in the hippocampal formation and cerebral cortex, suggesting increased expression of NF?B in brain areas affected by AD ( Terai et al., 1996). Thus, inflammation may be a causative factor in the pathogenesis of AD."

Article at:
http://www.sciencedirect.com/science/article/pii/S1319562X14000424